Description
Xigduo, a combination oral medication consisting of dapagliflozin and metformin, is utilized in the management of type 2 diabetes. This medication combines the actions of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which helps the kidneys eliminate glucose from the bloodstream, with metformin, which decreases glucose production in the liver and improves the body’s response to insulin.